Camizestrant plus ribociclib for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs, camizestrant and ribociclib, for people with a certain type of advanced breast cancer (HR+/HER2-). It is for those whose cancer has grown or spread despite previous hormone therapy. The goal is to see if this new combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of breast cancer called HR-positive and HER2-negative, which has spread or cannot be removed with surgery.
- You have already had at least 5 years of hormone therapy (including an aromatase inhibitor) after your first diagnosis, and your cancer has started growing again during or within a year of that therapy.
- You are an adult (18 or older) and either are postmenopausal or are premenopausal and willing to take a drug that suppresses ovarian function.
- You have not had any prior treatment with a type of drug called a SERD (such as fulvestrant or camizestrant), and you have not had any chemotherapy or other treatments for advanced disease.
- You are able to provide a tissue sample from your cancer (either from a new biopsy or a stored sample) and have adequate organ function (kidney, liver, blood counts).
- Your overall health is good (ECOG score 0 or 1), and you are not pregnant, breastfeeding, or unwilling to use highly effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
This trial tests whether adding the targeted therapy ribociclib (Kisqali) to radiation after surgery reduces the risk of breast cancer returning in patients with high-risk, hormone-positive breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.